Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab       DK0010272202

GENMAB

 SummaryChartsNewsRatingsCalendarCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq Omx Copenhagen
07/20/2016 07/21/2016 07/22/2016 07/25/2016 07/26/2016 Date
1159 1157 1148 1145 1210 Last
296712 169924 208426 180923 528993 Volume
-0.09% -0.17% -0.78% -0.26% +5.68% Change
Company
Genmab specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (57.6%); - income from research and development (22.7%); - other... 
Sector
Biotechnology & Medical Research
Calendar
11/06 | 11:00amEarnings Release
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
08/14Genmab Announces Financial Results for the First Half of 2019 and Updates 201..
GL
07/24GENMAB : Announces the Closing of Over-Allotment Option in Initial Public Offeri..
AQ
07/24GENMAB A/S : has published its Articles of Association
AQ
07/23Genmab Announces the Closing of Over-Allotment Option in Initial Public Offer..
GL
07/22Genmab Announces the Completion of its Initial Public Offering of American De..
GL
07/22MORGAN STANLEY : Genmab Announces Full Exercise of Underwriters' Over-Allotment ..
AQ
07/22GENMAB A/S : - Major Shareholder Announcement
AQ
07/19Major Shareholder Announcement
GL
07/19Genmab Announces Full Exercise of Underwriters' Over-Allotment Option in Init..
GL
07/19GENMAB : Announces Submission of Extension of Marketing Authorization to Europea..
AQ
More news
Analyst Recommendations on GENMAB
More recommendations
Stock Trading Strategies
GENMAB - 02/07
A good level to buy
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Bio Therapeutic Drugs
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB14.24%13 013
GILEAD SCIENCES0.94%79 622
VERTEX PHARMACEUTICALS11.60%46 554
REGENERON PHARMACEUTICALS-20.52%32 073
GENMAB26.56%13 013
SAREPTA THERAPEUTICS INC14.50%9 067